 Ampio Pharmaceuticals Inc NYSE: AMPE received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results. In March, Ampio announced data from the modified Intent-To-Treat mITT population n618 in the AP-013 study of Ampion in. 